VISEN Pharma buys back 9,200 shares for HK$0.21 million, marginally trimming free float

Bulletin Express05-18

VISEN Pharmaceuticals announced a repurchase of 9,200 ordinary shares on 18 May 2026 via on-exchange transactions at prices between HK$22.84 and HK$22.98, averaging HK$22.95 per share. The total consideration amounted to HK$0.21 million.

Following the transaction, VISEN’s issued share capital (excluding treasury shares) declined 0.008 % to 113.92 million shares, while the same number of shares—9,200—has been transferred to treasury stock. The overall issued share count, including treasury shares, remains unchanged at 113.93 million.

The buyback was executed under the share repurchase mandate approved on 27 June 2025, which authorises the company to repurchase up to 11.39 million shares. To date, 9,200 shares—representing 0.08 % of the issued share base as at the mandate date—have been repurchased under this authority.

In accordance with Hong Kong Stock Exchange regulations, VISEN is subject to a moratorium on issuing new shares or selling treasury shares until 17 June 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1131181047?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-18 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1131181047","market":"us","top_or_hot":-1,"title":"VISEN Pharma buys back 9,200 shares for HK$0.21 million, marginally trimming free float","media":"Bulletin Express","content":"<p>VISEN Pharmaceuticals announced a repurchase of 9,200 ordinary shares on 18 May 2026 via on-exchange transactions at prices between HK$22.84 and HK$22.98, averaging HK$22.95 per share. The total consideration amounted to HK$0.21 million.</p>\n<p>Following the transaction, VISEN’s issued share capital (excluding treasury shares) declined 0.008 % to 113.92 million shares, while the same number of shares—9,200—has been transferred to treasury stock. The overall issued share count, including treasury shares, remains unchanged at 113.93 million.</p>\n<p>The buyback was executed under the share repurchase mandate approved on 27 June 2025, which authorises the company to repurchase up to 11.39 million shares. To date, 9,200 shares—representing 0.08 % of the issued share base as at the mandate date—have been repurchased under this authority.</p>\n<p>In accordance with Hong Kong Stock Exchange regulations, VISEN is subject to a moratorium on issuing new shares or selling treasury shares until 17 June 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VISEN Pharma buys back 9,200 shares for HK$0.21 million, marginally trimming free float</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVISEN Pharma buys back 9,200 shares for HK$0.21 million, marginally trimming free float\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-18 20:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>VISEN Pharmaceuticals announced a repurchase of 9,200 ordinary shares on 18 May 2026 via on-exchange transactions at prices between HK$22.84 and HK$22.98, averaging HK$22.95 per share. The total consideration amounted to HK$0.21 million.</p>\n<p>Following the transaction, VISEN’s issued share capital (excluding treasury shares) declined 0.008 % to 113.92 million shares, while the same number of shares—9,200—has been transferred to treasury stock. The overall issued share count, including treasury shares, remains unchanged at 113.93 million.</p>\n<p>The buyback was executed under the share repurchase mandate approved on 27 June 2025, which authorises the company to repurchase up to 11.39 million shares. To date, 9,200 shares—representing 0.08 % of the issued share base as at the mandate date—have been repurchased under this authority.</p>\n<p>In accordance with Hong Kong Stock Exchange regulations, VISEN is subject to a moratorium on issuing new shares or selling treasury shares until 17 June 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02561","symbol_name":"维昇药业-B","start_time":0,"source_url":"","article_id":"1131181047","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1131181047","pubTimestamp":1779105791,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"VISEN Pharmaceuticals announced a repurchase of 9,200 ordinary shares on 18 May 2026 via on-exchange transactions at prices between HK$22.84 and HK$22.98, averaging HK$22.95 per share. The total...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02561":"维昇药业-B"},"translate_title":"维森制药以21万港元回购9,200股自由流通量小幅削减","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02561":1},"content_text":"VISEN Pharmaceuticals announced a repurchase of 9,200 ordinary shares on 18 May 2026 via on-exchange transactions at prices between HK$22.84 and HK$22.98, averaging HK$22.95 per share. The total consideration amounted to HK$0.21 million.\nFollowing the transaction, VISEN’s issued share capital (excluding treasury shares) declined 0.008 % to 113.92 million shares, while the same number of shares—9,200—has been transferred to treasury stock. The overall issued share count, including treasury shares, remains unchanged at 113.93 million.\nThe buyback was executed under the share repurchase mandate approved on 27 June 2025, which authorises the company to repurchase up to 11.39 million shares. To date, 9,200 shares—representing 0.08 % of the issued share base as at the mandate date—have been repurchased under this authority.\nIn accordance with Hong Kong Stock Exchange regulations, VISEN is subject to a moratorium on issuing new shares or selling treasury shares until 17 June 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1131181047","isCrawlerRequest":true}